tetano
Editor, Senior Moderator
Bull Exp Biol Med. 2010 May;149(5):612-4.
Antiviral Activity of Anaferon (Pediatric Formulation) in Mice Infected with Pandemic Influenza Virus A(H1N1/09).
[Article in English, Russian]
Shishkina LN, Skarnovich MO, Kabanov AS, Sergeev AA, Olkin SE, Tarasov SA, Belopolskaya MV, Sergeeva SA, Epstein OI, Malkova EM, Stavsky EA, Drozdov IG.
Vector Research Center of Virology and Biotechnology, Federal Service on Surveillance for Consumer Rights Protection and Human WellBeing, Kol'tsovo, Novosibirsk region; Materia Medica Holding ResearchandProduction Company, Moscow, Russia. shish@vector.nsc.ru.
Abstract
Anaferon (pediatric formulation) administered in the therapeutic-and-prophylactic regimen to mice receiving intranasally 100% infecting dose of A/California/07/2009(H1N1)v influenza virus exhibited an antiviral effect and 10-fold reduced the production of influenza virus in the lungs of infected mice on days 4, 6, and 8 after infection compared to the control (distilled water). The efficiency of Anaferon (pediatric formulation) administered before and after infection with A/California/07/2009(H1N1)v influenza virus was not inferior to the use of Tamiflu after infection.
PMID: 21165400 [PubMed - in process]
http://www.ncbi.nlm.nih.gov/pubmed/21165400
Antiviral Activity of Anaferon (Pediatric Formulation) in Mice Infected with Pandemic Influenza Virus A(H1N1/09).
[Article in English, Russian]
Shishkina LN, Skarnovich MO, Kabanov AS, Sergeev AA, Olkin SE, Tarasov SA, Belopolskaya MV, Sergeeva SA, Epstein OI, Malkova EM, Stavsky EA, Drozdov IG.
Vector Research Center of Virology and Biotechnology, Federal Service on Surveillance for Consumer Rights Protection and Human WellBeing, Kol'tsovo, Novosibirsk region; Materia Medica Holding ResearchandProduction Company, Moscow, Russia. shish@vector.nsc.ru.
Abstract
Anaferon (pediatric formulation) administered in the therapeutic-and-prophylactic regimen to mice receiving intranasally 100% infecting dose of A/California/07/2009(H1N1)v influenza virus exhibited an antiviral effect and 10-fold reduced the production of influenza virus in the lungs of infected mice on days 4, 6, and 8 after infection compared to the control (distilled water). The efficiency of Anaferon (pediatric formulation) administered before and after infection with A/California/07/2009(H1N1)v influenza virus was not inferior to the use of Tamiflu after infection.
PMID: 21165400 [PubMed - in process]
http://www.ncbi.nlm.nih.gov/pubmed/21165400